Long-term outcome of prenatal dexamethasone treatment of 21-hydroxylase deficiency

Endocrine Development

Volumn 20, Issue , 2010, Pages 96-105

  Lajic, Svetlana ^a   Nordenström, Anna ^a   Hirvikoski, Tatja ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE;

ARTICLE; BEHAVIOR DISORDER; COGNITION; CONGENITAL ADRENAL HYPERPLASIA; EDEMA; GESTATIONAL AGE; HEART DISEASE; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LEARNING; LONG TERM MEMORY; MASCULINITY; METABOLIC DISORDER; MOOD DISORDER; NONHUMAN; PRENATAL PERIOD; PRIORITY JOURNAL; PSYCHOLOGICAL WELL BEING; SIDE EFFECT; SLEEP DISORDER; SOCIAL PHOBIA; STRIA; TEMPERAMENT; TREATMENT OUTCOME; WEIGHT GAIN;

ADRENAL HYPERPLASIA, CONGENITAL; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT, NEWBORN; MALE; MODELS, BIOLOGICAL; PRENATAL CARE; PRENATAL DIAGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 78751530636     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000321228     Document Type: Article

References (27)

1. David M, Forest MG: Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J Pediatr 1984;105:799-803.
2. Goto M, Piper Hanley K, Marcos J, et al: In humans, early cortisol biosynthesis provides a mechanism to safeguard female sexual development. J Clin Invest 2006;116:953-960.
3. Rijnders RJ, van der Schoot CE, Bossers B, et al: Fetal sex determination from maternal plasma in pregnancies at risk for congenital adrenal hyperplasia. Obstet Gynecol 2001;98:374-378.
4. Morel Y, Tardy V, Costa JM, et al: 21-Hydroxylase deficiency: new strategies emerging from molecular studies. Ann Endocrinol (Paris) 2003;64:456-470.
5. Bischoff FZ, Lewis DE, Simpson JL: Cell-free fetal DNA in maternal blood: kinetics, source and structure. Hum Reprod Update 2005;11:59-67.
6. Forest MG, David M, Morel Y: Prenatal diagnosis and treatment of 21-hydroxylase deficiency. J Steroid Biochem Mol Biol 1993;45:75-82.
7. Forest MG, Dorr HG: Prenatal therapy in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: retrospective follow-up study of 253 treated pregnancies in 215 families. Endocrinologist 2003; 13:252-259.
8. Mercado AB, Wilson RC, Cheng KC, et al: Prenatal treatment and diagnosis of congenital adrenal hyperplasia owing to steroid 21-hydroxylase deficiency. J Clin Endocrinol Metab 1995;80:2014-2020.
9. Carlson AD, Obeid JS, Kanellopoulou N, et al: Congenital adrenal hyperplasia: update on prenatal diagnosis and treatment. J Steroid Biochem Mol Biol 1999;69:19-29.
10. New MI, Carlson A, Obeid J, et al: Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J Clin Endocrinol Metab 2001;86: 5651-5657.
11. Lajic S, Wedell A, Bui TH, et al: Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998;83:3872-3880.
12. Barker DJ, Eriksson JG, Forsen T, Osmond C: Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol 2002;31:1235-1239.
13. Seckl JR, Holmes MC: Mechanisms of disease: glucocorticoids, their placental metabolism and fetal programming of adult pathophysiology. Nat Clin Pract Endocrinol Metab 2007:3:479-488.
14. Seckl JR: Prenatal glucocorticoids and long-term programming. Eur J Endocrinol 2004;151(suppl 3): 49-62.
15. Sloboda DM, Timothy JMM, Li S, et al: Prenatal betamethasone exposure results in pituitary-adrenal hyporesponsiveness in adult sheep. Am J Physiol 2007;292:E61-E70.
16. Uno H, Eisele S, Sakai A, et al: Neurotoxicity of glucocorticoids in the primate brain. Horm Behav 1994;28:336-348.
17. De Vries A, Holmes MC, Heijnis A, et al: Prenatal dexamethasone exposure induces changes in nonhuman primate offspring cardiometabolic and hypothalamic-pituitary-adrenal axis function. J Clin Invest 2007;117:1058-1067.
18. Dalziel SR, Walker NK, Parag V, et al: Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. Lancet 2005;365:1856-1862.
19. Lajic S, Nordenstrom A, Hirvikoski T: Long-term outcome of prenatal treatment of congenital adrenal hyperplasia. Endocr Dev 2008;13:82-98.
20. Baud O, Sola A: Corticosteroids in perinatal medicine: how to improve outcomes without affecting the developing brain? Semin Fetal Neonatal Med 2007;12:273-279.
21. Hirvikoski T, Nordenstrom A, Lindholm T, et al: Long-term follow-up of prenatally treated children at risk for congenital adrenal hyperplasia: does dexamethasone cause behavioural problems? Eur J Endocrinol 2008;159:309-316.
22. Hirvikoski T, Nordenstrom A, Lindholm T, et al: Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J Clin Endocrinol Metab 2007;92: 542-548.
23. Meyer-Bahlburg HF, Dolezal C, Baker SW, et al: Cognitive and motor development of children with and without congenital adrenal hyperplasia after early-prenatal dexamethasone. J Clin Endocrinol Metab 2004;89:610-614.
24. Trautman PD, Meyer-Bahlburg HF, Postelnek J, New MI: Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: results of a pilot study. Psychoneuroendocrinology 1995;20:439-449.
25. Baddeley A: Working Memory. Oxford, Clarendon Press, 1986.
26. Arnsten AF: Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry 2006;67(suppl 8):7-12.
27. Lajic S, Nordenstrom A, Ritzen EM, Wedell A:: Prenatal treatment of congenital adrenal hyperplasia. Eur J Endocrinol 2004;151(suppl 3):63-69.